HCW Biologics Inc. (HCWB) — SEC Financial Statements & Analysis

HCW Biologics Inc. (HCWB) is a pharmaceutical preparations company, incorporated in DE. HCW Biologics Inc. trades on Nasdaq as: HCWB. HCW Biologics Inc. (HCWB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, HCW Biologics Inc. carries a market cap of $6.63M, a P/E ratio of -0.33x, a P/B ratio of 0.89x, a P/S ratio of 0.99x, an enterprise value of $12.45M, and an EV/EBITDA multiple of -1.76x. On profitability, it posts a gross margin of 95.91%, an operating margin of -114.02%, a net margin of -296.39%, a Return on Equity (ROE) of -540.18%, a Return on Assets (ROA) of -71.56%, and a Return on Invested Capital (ROIC) of -86.61%. Per share, it reports EPS of $-15.00, diluted EPS of $-15.00, free cash flow per share of $-9.14, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 707.02% year-over-year, net income growth of 74.74% year-over-year, and EPS growth of -60.96% year-over-year. On the balance sheet, it maintains a current ratio of 0.06x, a quick ratio of 0.05x, working capital of $-17.51M, a debt-to-equity ratio of 2.60x, a debt ratio of 0.72, an interest coverage ratio of -13.44x, free cash flow of $-12.14M (TTM), and net debt of $5.82M. Figures sourced from SEC EDGAR.

Market Cap

$6.63M

P/E TTM

-0.33x

EPS TTM

$-15.00

P/B TTM

0.89x

ROE TTM

-540.18%

ROA TTM

-71.56%

Debt To Equity

2.60x

Free Cash Flow TTM

$-12.14M

Net Revenue TTM Growth 1Y

707.02%

Data as of 2026-06-30 · Source: SEC EDGAR